Use the labels in the right column to find what you want. Or you can go thru them one by one, there are only 29,112 posts. Searching is done in the search box in upper left corner. I blog on anything to do with stroke.DO NOT DO ANYTHING SUGGESTED HERE AS I AM NOT MEDICALLY TRAINED, YOUR DOCTOR IS, LISTEN TO THEM. BUT I BET THEY DON'T KNOW HOW TO GET YOU 100% RECOVERED. I DON'T EITHER, BUT HAVE PLENTY OF QUESTIONS FOR YOUR DOCTOR TO ANSWER.
Changing stroke rehab and research worldwide now.Time is Brain!trillions and trillions of neuronsthatDIEeach day because there areNOeffective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.
What this blog is for:
My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.
Wednesday, January 31, 2018
Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial
This is the first long-term (18 months) double-blind, placebo controlled trial of a bioavailable
form of curcumin (Theracurmin® containing 90 mg of curcumin twice daily) in non-demented adults.
•
We found that daily oral Theracurmin led to significant memory and attention benefits.
•
FDDNP-PET
scans performed pre- and post-treatment suggested that behavioral and
cognitive benefits are associated with decreases in plaque and tangle accumulation in brain regions modulating mood and memory.
•
Curcumin's cognitive benefits may stem from its anti-inflammatory and/or anti-amyloid brain effects.
Objective
Because
curcumin's anti-inflammatory properties may protect the brain from
neurodegeneration, we studied its effect on memory in non-demented
adults and explored its impact on brain amyloid and tau accumulation
using
2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile
positron emission tomography (FDDNP-PET).
Methods
Forty
subjects (age 51–84 years) were randomized to a bioavailable form of
curcumin (Theracurmin® containing 90 mg of curcumin twice daily
[N = 21]) or placebo (N = 19) for 18 months. Primary outcomes were
verbal (Buschke Selective Reminding Test [SRT]) and visual (Brief Visual
Memory Test-Revised [BVMT-R]) memory, and attention (Trail Making A)
was a secondary outcome. FDDNP-PET signals (15 curcumin, 15 placebo)
were determined in amygdala, hypothalamus, medial and lateral temporal,
posterior cingulate, parietal, frontal, and motor (reference) regions.
Mixed effects general linear models controlling for age and education,
and effect sizes (ES; Cohen's d) were estimated.
Results
SRT
Consistent Long-Term Retrieval improved with curcumin (ES = 0.63,
p = 0.002) but not with placebo (ES = 0.06, p = 0.8; between-group:
ES = 0.68, p = 0.05). Curcumin also improved SRT Total (ES = 0.53,
p = 0.002), visual memory (BVMT-R Recall: ES = 0.50, p = 0.01; BVMT-R
Delay: ES = 0.51, p = 0.006), and attention (ES = 0.96, p < 0.0001)
compared with placebo (ES = 0.28, p = 0.1; between-group: ES = 0.67,
p = 0.04). FDDNP binding decreased significantly in the amygdala with
curcumin (ES = −0.41, p = 0.04) compared with placebo (ES = 0.08,
p = 0.6; between-group: ES = 0.48, p = 0.07). In the hypothalamus, FDDNP
binding did not change with curcumin (ES = −0.30, p = 0.2), but
increased with placebo (ES = 0.26, p = 0.05; between-group: ES = 0.55,
p = 0.02).
Conclusions
Daily
oral Theracurmin may lead to improved memory and attention in
non-demented adults. The FDDNP-PET findings suggest that symptom
benefits are associated with decreases in amyloid and tau accumulation
in brain regions modulating mood and memory.
No comments:
Post a Comment